newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of